# Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

> **NCT00182533** · PHASE4 · TERMINATED · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 170 (estimated)

## Conditions studied

- Phobia, Social
- Panic Disorder
- Agoraphobia
- Obsessive-Compulsive Disorder
- Anxiety Disorders
- Major Depressive Disorder

## Interventions

- **DRUG:** Sertraline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00182533
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-07
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 170 (ESTIMATED)
- **Why stopped:** Study drug could not be re-supplied
- **Last updated:** 2018-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00182533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00182533, "Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00182533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*